American Joint Committee on Cancer
(AJCC) Version 9 Staging Protocols: What
is new and what is old?

Elliot A. Asare, MD, MS, FACS Chair, Editorial Committee of the AJCC University of Utah Huntsman Cancer Institute Salt Lake City, Utah

1

Disclosures

• I have no relevant financial disclosures

2

Objectives

- Why we stage cancer
- \bullet The case for change from 8^{th} Edition to Version 9
- Overview of the Version 9 process
- Current Version 9 protocols
- AJCC subscription model

Why we stage cancer

- Critical benchmark for defining prognosis and for determining the best treatment approach for patients
- \bullet Forms the basis for $\mbox{\bf defining groups}$ for inclusion in clinical trials
- Forms the basis for understanding the changes in **population** cancer incidence, **extent of disease** at initial presentation, and the **overall** impact of improvements in cancer treatment


4


ACS AJCC American Joi American Co	int Committee on Cancer llege of Surgeons
From 8 th Edition Manual	To Version 9 Staging System
Hardcopy book	Leverages Content Management infrastructure to support multiple products
Chapters	Protocols for each disease site
Published every 5-7 years	AJCC will release ~ 5 protocols each year
Entire manual (all chapters) published simultaneously	Protocols published disease site by disease site based on needs of clinical care & surveillance communities and in coordination with WHO Blue Book update cycle
Print manual → "static"	Electronic platform facilitates rapid integration of updated staging information into EHR and cancer registry software as well as other products

5

AJCC Version 9: What's new?

- All disease sites will have evidence to drive any proposed changes from the 8^{th} edition
- Data review is formalized through the Evidence-based Medicine
- The protocol is a synoptically formatted document with tabular data up front, some new sections, and a standardized set of content
- Overall cycle times for release are based upon:
 The deadlines set by AJCC partners in the Cancer Surveillance Community
 The requirements for digital information by software vendors and the CDC






Published Version 9 Staging Protocols Cervix Anus Appendix Central Nervous System Vulva Gl Neuroendocrine Tumors Pancreas Ileum/jejunum Colon and rectum Stomach Duodenum & Ampulla Appendix

Disease site Cervix	Version 9 vs 8th Edition HPV status with p16 Imaging Node categories
Anus	Eliminated stage 0 Stage IIB: T1N1M0, T2N1M0 Stage IIIA: T3N0M0, T3N1M0
Appendix	 Mucinous, Non-mucinous and Signet-ring cell survival curves LAMN staging explanations
Brain and Spinal Cord	Improved clarity of content Medulloblastoma M category for metastasis
Vulva	New T4 categoryChanges to N categoriesImaging
GI Neuroendocrine Tumors	T1NXM0 assigned to pathological stage I Discussion of endoscopic resection

10



11

Key Takeaways

- AJCC Version 9 protocol changes based on highest level of available evidence
- Version 9 is a fully digitally-based system
- Subscription model for AJCC Staging Online product

Acknowle	edgement
----------	----------

- Marty Madera, CPHIMS
- Elaine Alexander, PhD
- Donna Gress, RHIT, ODS-C
- Aleisha Williams, MBA, ODS-C
- Chanjuan Shi, MD, PhD
- Jennifer Plichta, MD, MS, FACS
- Kay Washington, MD, PhD
- Members of AJCC Editorial, Executive Committee and Expert Panels

1	3
_	_